The potential of AFSC-EV therapy for treating lung underdevelopment

Congenital diaphragmatic hernia (CDH) is a birth defect where a hole in the diaphragm allows abdominal organs to move into the chest, impeding lung development. This can result in pulmonary hypoplasia, where the lungs are underdeveloped and cannot function properly. Recently, researchers at The Hospital for Sick Children have explored a new treatment involving extracellular vesicles (EVs) derived from amniotic fluid stem cells (AFSC-EVs) to address this issue.

What are Extracellular Vesicles (EVs)?

Extracellular vesicles are tiny particles released by cells that can transfer molecules like proteins and RNA between cells. They play a crucial role in cell communication and have potential therapeutic uses.

The Study: How AFSC-EVs Help Lung Development in CDH

  1. Research Method:
    • The researchers conducted an experiment using fetal rats with CDH. They treated these rats with AFSC-EVs and compared the results with a control group that received a placebo (vehicle).
  2. Single-Nucleus RNA Sequencing (snRNA-seq):
    • To understand the effects of AFSC-EVs on lung development, the team used a technique called single-nucleus RNA sequencing (snRNA-seq). This method allows scientists to examine gene expression in individual cells from the lungs, providing detailed insights into how different cell types respond to the treatment.
  3. Key Findings:
    • Lung Morphogenesis and Differentiation: The AFSC-EVs helped the lungs develop more normally by promoting the branching of lung tissues (morphogenesis) and the differentiation of epithelial cells, which are essential for lung function.
    • Inflammation Reduction: The untreated CDH-affected lungs showed signs of inflammation with an increase in macrophages, a type of immune cell. The AFSC-EV treatment reduced this inflammatory response, indicating a potential mechanism by which the therapy aids lung development.
  4. Validation with Human Samples:
    • The researchers also examined human fetal lung samples from CDH cases and confirmed the presence of increased macrophages, mirroring the findings in the rat model. This supports the relevance of their results to human CDH.

In vivo administration of AFSC-EVs reaches fetal lungs and
improves lung development in fetal rats with CDH

(A) Representative IVIS Spectrum cross-sectional images from three-dimensional (3D) bioluminescence reconstructions of whole fetuses at E21.5. Fetuses randomly received either saline injection (left), IV injection of ExoGlowVivo-stained AFSC-EVs (middle), or IA injection of ExoGlowVivo-stained AFSC-EVs (right) at E18.5 in control fetuses (top row) or fetuses with pulmonary hypoplasia/CDH that received nitrofen (bottom row). Scale bar shows background-corrected fluorescence in pmol M−1 cm−1. Control+saline (n = 3), Control+IV-AFSC-EVs (n = 3), Control+IA-AFSC-EVs (n = 7), Nitrofen+saline (n = 6), Nitrofen+IV-AFSC-EVs (n = 3), and Nitrofen+IA-AFSC-EVs (n = 16). (B) Representative 2D optical images of dissected fetal lungs from the same conditions described in (A), quantified as radiant efficiency [p/s/cm2/sr]/[μW/cm2]. Control+saline (n = 3), Control+IV-AFSC-EVs (n = 3), Control+IA-AFSC-EVs (n = 3), Nitrofen+saline (n = 3), Nitrofen+IV-AFSC-EVs (n = 4), and Nitrofen+IA-AFSC-EVs (n = 9). (C) Representative histology images (hematoxylin and eosin) of fetal lungs from Control+saline, CDH+saline, and CDH+AFSC-EV fetuses. Each condition included fetal lungs from n = 5 experiments. Scale bars, 50 μm. (D) Differences in number of alveoli (RAC) in Control+saline (n = 8), CDH+saline (n = 8), and CDH+AFSC-EVs (n = 9) quantified in at least five fields per fetal lung. ****P < 0.0001; ***P < 0.001; ns, not significant. (E) Gene expression of lung developmental markers Fgf10, Pdpn, and Sftpc and Sftpa. Control+saline (n = 5), CDH+saline (n = 5), and CDH+AFSC-EVs (n = 5). **P < 0.01; *P < 0.05. (F) Representative immunofluorescence images of PDPN (red; top) and SPC (green; bottom) protein expression between Control+saline, CDH+saline, and CDH+AFSC-EV fetuses [4′,6-diamidino-2-phenylindole (DAPI); blue]. Scale bars, 50 μm. (G) Western blot analysis of PDPN and SPC expression in fetal lung quantified by signal intensity normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Control+saline (n = 6), CDH+saline (n = 7), and CDH+AFSC-EVs (n = 6). Groups were compared using Kruskal-Wallis (post hoc Dunn’s nonparametric comparison) for (D) RAC and (E) Fgf10, Pdpn, and Sftpc and one-way ANOVA (Tukey post-test) for (E) Sftpa and (G), according to Shapiro-Wilk normality test.Implications and Future Directions

This study highlights the potential of AFSC-EV therapy to improve lung development in fetuses with CDH by promoting normal tissue growth and reducing harmful inflammation. These findings pave the way for future research and development of EV-based treatments for other conditions involving lung development and inflammation.

The research on AFSC-EV therapy for CDH represents a promising step forward in treating this challenging birth defect. By understanding how these vesicles interact with fetal lung cells and reduce inflammation, scientists are moving closer to effective treatments that could significantly improve outcomes for affected infants. This study underscores the importance of exploring innovative therapies and the potential of stem cell-derived treatments in regenerative medicine.

Antounians L, Figueira RL, Kukreja B, Litvack ML, Zani-Ruttenstock E, Khalaj K, Montalva L, Doktor F, Obed M, Blundell M, Wu T, Chan C, Wagner R, Lacher M, Wilson MD, Post M, Kalish BT, Zani A. (2024) Fetal hypoplastic lungs have multilineage inflammation that is reversed by amniotic fluid stem cell extracellular vesicle treatment. Sci Adv 10(30):eadn5405. [article]

Leave a Reply

Your email address will not be published. Required fields are marked *

*